Q2 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript
Key Points
- INO-3107 is on track for the October 30, 2026 PDUFA date, with the FDA completing its late-cycle review and all pre-licensure inspections.
- INO-3107 demonstrated strong efficacy in clinical trials, with the majority of patients experiencing a 50-100% reduction in surgery in year one and continued improvement in year two.
- INO-3107 offers a differentiated safety profile, not requiring scoping and surgery during the dosing window, unlike existing treatments like papsimios.
- The company expects to receive seven years of orphan drug market exclusivity for INO-3107 if approved, providing a competitive advantage.
- Positive Phase 3 data from Apollo Bio for VGX-3100 in China validates the potential of Inovio's DNA medicine platform for HPV-related diseases.
- The company has strengthened its balance sheet with an $18.3 million equity offering, extending its cash runway into late first quarter 2027 and through a potential launch.
- Operating expenses decreased by 19% in Q2 2026 compared to the same period in 2025, reflecting disciplined cost management.
- The FDA has not yet provided preliminary conclusions on INO-3107's eligibility for accelerated approval, which remains a potential review issue.
- The company's cash runway extends only into late first quarter 2027, and further capital raising may be needed if launch is delayed or revenue is slower than expected.
- INO-3107 faces competition from papsimios, which has already been approved and has shown early uptake with approximately 200 patients treated.
- The company is still awaiting FDA feedback on the design of the confirmatory trial, which could impact timelines and resources.
- The net loss for Q2 2026 was $6 million, and the company continues to burn cash, with an estimated operational net cash burn of $18 million for Q3 2026.
- The company's reliance on partnerships, such as Apollo Bio for VGX-3100, means it has limited control over the development and commercialization of certain pipeline candidates.
Good afternoon, ladies and gentlemen, and welcome to the Inovio Second Quarter 2026 Financial Assault Conference Call. At this time, all lines are in a listen-only mode.
Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press *0 for the operator.
This call is being recorded on Wednesday, August 12, 2026.
I would now like to turn the conference over to Jennie Willson, Director of Communications. Please go ahead.
Thank you. Good afternoon, and thank you for joining the Adnovio Second Quarter 2026 Financial Results Conference Call.
Joining me today are Dr. Jackie Shea, President and Chief Executive Officer Dr. Mike Sumner, Chief Medical Officer Steve Ege, Chief Commercial Officer and Peter Keyes, Chief Financial Officer. Today's call will review our corporate and financial information for the quarter ended June 30, 2026, as well as provide a general business update.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
